Welcome!
DBS Group Research
Broker's Calls
Analysts mixed on MLT following 2QFY2023 results amid volatile China outlook
Citi analyst Brandon Lee says MLT’s 2QFY2023 results revealed more negatives than positives.
October 27, 2022
Broker's Calls
Analysts maintain 'buy' on Keppel REIT with lower TPs following 9MFY2022 results announcement
The analysts describe the anniversary distribution as a bold and rare move, especially in such a challenging environment.
October 26, 2022
Broker's Calls
Private hospitals may benefit from rise in Covid-19 cases: DBS
DBS has kept “buy” on Raffles Medical Group and IHH Healthcare with target prices of $1.63 and RM7.90 ($2.37) respectively.
October 25, 2022
Broker's Calls
Analysts remain positive on banks ahead of 3QFY2022 results due to NIM expansions
CGS-CIMB remains “overweight” on the sector while DBS expects the sector to see “higher absolute dividends” for FY2022.
October 21, 2022
Broker's Calls
DBS remains positive on Sea as it sees e-commerce-led profitability in sight
The brokerage has, however, lowered its TP to US$100 with a bear-case TP of US$63.
October 21, 2022
Broker's Calls
DBS maintains 'hold' on Grab with lower TP as market focuses on profitability
DBS expects slowdown in the financial services segment as ebitda losses have increased.
October 21, 2022
Broker's Calls
Brokers' Digest: City Developments, SATS, CapitaLand Investment, AEM Holdings, Mapletree Industrial Trust
See what the analysts have to say this week.
October 21, 2022
Broker's Calls
Analysts see CDG as 'attractively priced' and 'grossly oversold' on fundamental basis
Analysts from DBS Group Research and Maybank Securities are expecting CDG to see sequential improvement in its 3QFY2022 update.
October 20, 2022
Singapore economy
Analysts mostly raise inflation forecasts for 2023 after MAS's tightening move
Inflation is likely to remain elevated in 2022; off-cycles are likely to be done for 2022, note the analysts.
October 19, 2022
Broker's Calls
DBS slashes Grand Venture Tech's TP by almost half on weaker semicon market
Compared to the semiconductor segment, DBS expects GVT’s life sciences and medical segments to remain relatively stable.
October 19, 2022